Valuation: EyePoint, Inc.

Market Cap 29Cr 26Cr 24Cr 22Cr 42Cr 2.84TCr 42Cr 293.1Cr 114.84Cr 1.45TCr 110.07Cr 107.67Cr 4.64TCr P/E 2026 *
-0.94x
P/E 2027 * -1.29x
Enterprise Value -2.97Cr -2.65Cr -2.47Cr -2.24Cr -4.23Cr -287.16Cr -4.25Cr -30Cr -12Cr -146.4Cr -11Cr -11Cr -469.82Cr EV / Sales 2026 *
-17.7x
EV / Sales 2027 * -1.19x
Free-Float
96.47%
Yield 2026 *
-
Yield 2027 * -
1 day-1.73%
1 week+4.62%
Current month+3.98%
1 month-20.00%
3 months-76.90%
6 months-76.04%
Current year-81.39%
1 week 3.05
Extreme 3.05
3.57
1 month 3.05
Extreme 3.05
4.34
Current year 3.05
Extreme 3.05
18.87
1 year 3.05
Extreme 3.05
19.11
3 years 3.05
Extreme 3.05
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
39.4
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Others

Chief Financial Officer

-1,39,906 0.1669%
18/08/26 Buy

Director

10,600 0.0126%
10/07/26 Exercice

Chief Executive Officer

41,393 0.0494%
Change 5-day change 1-year change 3-year change Capi.($)
-1.73%+4.62%-74.94%-61.14% 29Cr
+0.83%+3.19%+41.49%+103.56% 1,05100Cr
+1.93%+2.11%+37.08%+65.09% 63TCr
+1.49%+5.19%+19.94%+85.69% 49TCr
+2.26%+0.90%+69.32%+40.53% 36TCr
+1.45%+3.50%+23.29%+41.62% 34TCr
+1.17%+2.37%+13.47%+33.64% 27TCr
+0.89%+1.08%-6.13%+9.29% 25TCr
+1.82%+2.94%+42.99%+52.95% 22TCr
+2.77%+4.44%+29.01%+98.99% 19TCr
Average +1.29%+2.74%+19.55%+47.02% 38.04TCr
Weighted average by Cap. +1.47%+2.44%+33.35%+69.00%

Financials

2026 *2027 *
Net sales 16.8L 15L 13.96L 12.69L 23.97L 16Cr 24.07L 1.68Cr 65.81L 8.29Cr 63.08L 61.7L 27Cr 1.79Cr 1.6Cr 1.49Cr 1.35Cr 2.56Cr 173.49Cr 2.57Cr 18Cr 7.02Cr 88Cr 6.73Cr 6.58Cr 283.84Cr
Net income -34Cr -31Cr -29Cr -26Cr -49Cr -3.33TCr -49Cr -343.95Cr -134.77Cr -1.7TCr -129.17Cr -126.35Cr -5.45TCr -29Cr -26Cr -24Cr -22Cr -42Cr -2.85TCr -42Cr -294.46Cr -115.38Cr -1.45TCr -110.58Cr -108.17Cr -4.66TCr
Net Debt -32Cr -29Cr -27Cr -24Cr -46Cr -3.12TCr -46Cr -322.77Cr -126.47Cr -1.59TCr -121.22Cr -118.56Cr -5.11TCr -31Cr -28Cr -26Cr -24Cr -45Cr -3.04TCr -45Cr -314.43Cr -123.2Cr -1.55TCr -118.08Cr -115.5Cr -4.98TCr
Projected Income Statement - Annual - EyePoint, Inc.
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
09/26/09 $3.400 -1.73% 19,40,466
08/26/08 $3.460 +4.22% 32,57,280
07/26/07 $3.320 +4.73% 30,21,955
06/26/06 $3.170 +0.63% 19,77,447
05/26/05 $3.150 -3.08% 27,63,906
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Ratings Surperformance© - EyePoint, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
3.400USD
Average target price
25.91USD
Spread / Average Target
+662.03%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - EyePoint, Inc.
  1. Stock Market
  2. Stocks
  3. EYPT Stock